Company / Profit Margin
Editas Medicine, Inc. Profit Margin History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-733.7%
FY2025
5-year range
-1118.3% / -127.8%
FY2021-FY2025
Trend
+34.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Profit Margin returned to growth in FY2025 after 2 years of decline, reaching -733.7%.
Based on SEC 10-K filings.
-733.7% in FY2025 with a 5-year CAGR of -389.4%.
Improved from -753.6% to -733.7% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- -605.9pp
- 5-Year Change
- -389.4pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, profit margin increased 34.4% year-over-year.
- Peak profit margin was recorded in FY2022.
- Lowest profit margin in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -733.7% | +34.4% |
| FY2024 | -1118.3% | -48.4% |
| FY2023 | -753.6% | -489.6% |
| FY2022 | -127.8% | +80.4% |
| FY2021 | -651.4% | -89.2% |
| FY2020 | -344.3% | +60.7% |
| FY2019 | -876.5% | +45.4% |
| FY2018 | -1605.5% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026